Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial

Highlights

1. Adjunctive semaglutide (1 mg once weekly) significantly reduced HbA1c levels compared to placebo (mean difference -0.25%) in patients with schizophrenia spectrum disorders and early glycemic dysregulation.

2. Participants treated with semaglutide experienced a mean weight loss of 9.2 kg over 26 weeks, alongside significant reductions in waist circumference and fat mass.

3. The intervention demonstrated a robust safety profile with no significant impact on psychiatric stability or symptom severity, addressing a major clinical concern for this population.

4. Early intervention with GLP-1 receptor agonists (GLP-1RAs) provides a viable strategy to counteract the metabolic side effects of second-generation antipsychotics like clozapine and olanzapine.

The Cardiometabolic Burden in Schizophrenia

Individuals diagnosed with schizophrenia spectrum disorders face a staggering mortality gap, living approximately 15 to 20 years less than the general population. While suicide and accidental death contribute to this statistic, the primary driver is premature cardiovascular disease. This elevated risk is multifactorial, stemming from sedentary lifestyles, high smoking rates, and socioeconomic disparities. However, a significant and often iatrogenic factor is the metabolic profile of second-generation antipsychotics (SGAs), specifically clozapine and olanzapine.

Clozapine and olanzapine are among the most effective treatments for refractory schizophrenia, yet they are notorious for inducing rapid weight gain, dyslipidemia, and insulin resistance. These metabolic changes often manifest shortly after treatment initiation, leading to early-stage glycemic abnormalities and, eventually, type 2 diabetes. Traditionally, clinicians have been hesitant to introduce intensive metabolic interventions early in the course of psychiatric treatment, often waiting until overt diabetes is present. The study by Sass et al. challenges this reactive paradigm, investigating whether early pharmacological intervention with semaglutide can arrest the progression of metabolic decline.

Study Design and Methodology

The trial was a multicenter, double-blind, placebo-controlled, randomized clinical trial conducted across three clinical sites in Denmark between September 2021 and August 2024. The researchers specifically targeted a vulnerable window: individuals aged 18 to 65 with schizophrenia spectrum disorders who had started clozapine or olanzapine within the previous five years. Crucially, participants had to exhibit early-stage glycemic dysregulation, defined as a hemoglobin A1c (HbA1c) between 5.4% and 7.4%, and were not yet receiving antidiabetic therapy.

A total of 73 participants were randomized into two groups: one receiving once-weekly subcutaneous semaglutide (titrated to 1 mg) and the other receiving a matching placebo. The intervention lasted 26 weeks. The primary endpoint was the change in HbA1c level from baseline to week 26. Secondary endpoints included changes in body weight, waist circumference, body composition (fat mass), lipid profiles, and psychiatric symptom stability as measured by the Positive and Negative Syndrome Scale (PANSS).

Key Findings: Glycemic Control and Weight Loss

The results of the trial provide compelling evidence for the efficacy of semaglutide in this specific psychiatric cohort. At the end of the 26-week period, semaglutide led to a statistically significant reduction in HbA1c compared to placebo, with a mean difference of -0.25% (95% CI, -0.33 to -0.16; P < .001). While a 0.25% reduction might appear modest in a general diabetic population, its clinical significance in this pre-diabetic group is underscored by the achievement of low-risk HbA1c levels. Specifically, 43% of the semaglutide group achieved an HbA1c below 5.4%, compared to only 3% in the placebo group.

The weight-associated outcomes were even more pronounced. The semaglutide group saw a mean weight reduction of 9.2 kg (95% CI, -13.3 to -5.1 kg) compared to the placebo group. This was accompanied by a significant decrease in waist circumference (-7.0 cm) and fat mass (-6.1 kg). Given that olanzapine and clozapine are often associated with weight gains of 10 kg or more within the first year of treatment, these findings suggest that semaglutide can effectively neutralize or even reverse the adipogenic effects of these antipsychotics.

Safety, Tolerability, and Psychiatric Stability

A paramount concern when introducing new medications to patients with schizophrenia is the potential for exacerbating psychiatric symptoms. The study found no significant differences between the semaglutide and placebo groups regarding PANSS scores, suicidal ideation, or other psychiatric adverse events. This provides essential reassurance to psychiatrists that GLP-1RAs can be used safely without compromising the primary psychiatric treatment goals.

Regarding general medical safety, the profile of semaglutide was consistent with findings in non-psychiatric populations. Gastrointestinal adverse events, such as nausea and vomiting, were more common in the semaglutide group but were generally categorized as mild and transient, occurring mostly during the dose-titration phase. Interestingly, no significant differences were observed in lipid levels or blood pressure, suggesting that the primary cardiovascular benefit in the short term is driven by glycemic and adiposity improvements.

Expert Commentary and Mechanistic Insights

The success of semaglutide in this population likely involves both peripheral and central mechanisms. SGAs like clozapine are known to disrupt hypothalamic appetite signaling, leading to hyperphagia and a loss of satiety. Semaglutide, as a GLP-1RA, acts on the same hypothalamic regions and the hindbrain to enhance satiety and slow gastric emptying, effectively counteracting the SGA-induced drive to overeat.

Furthermore, early-stage intervention is critical. In the early years of SGA treatment, the metabolic system may still possess enough plasticity to respond to GLP-1 sensitization. By intervening when HbA1c is in the 5.4%-7.4% range, clinicians can potentially prevent the irreversible beta-cell exhaustion that characterizes long-term type 2 diabetes. Experts note that this study reinforces the need for integrated care models where psychiatrists and endocrinologists work in tandem to monitor and manage the metabolic health of patients from the moment an SGA is prescribed.

Clinical Implications and Future Directions

The findings of this trial support a shift in clinical guidelines toward the earlier use of GLP-1RAs in patients treated with high-risk antipsychotics. Rather than waiting for the development of obesity or diabetes, the presence of early glycemic dysregulation or rapid weight gain should trigger the consideration of semaglutide.

However, several questions remain. The trial duration was 26 weeks; longer-term studies are needed to determine if these benefits are sustained and if they translate into a reduction in hard cardiovascular endpoints like myocardial infarction or stroke. Additionally, the cost-effectiveness of widespread GLP-1RA use in the psychiatric population must be evaluated, although the potential savings from avoided diabetes complications and hospitalizations are likely substantial.

Conclusion

The Sass et al. trial represents a significant step forward in the quest to reduce the health disparities faced by individuals with schizophrenia. By demonstrating that semaglutide can safely and effectively improve glycemic control and reduce weight in those taking clozapine or olanzapine, the study provides a powerful tool for clinicians to combat the cardiometabolic crisis in psychiatry. Moving forward, the integration of such metabolic therapies into standard psychiatric care may be essential to improving both the quality and length of life for this vulnerable population.

Funding and Registration

This study was supported by grants from the Novo Nordisk Foundation and other independent research bodies in Denmark. ClinicalTrials.gov Identifier: NCT04892199.

References

1. Sass MR, Klausen MK, Schwarz CR, et al. Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(2):128-138. doi:10.1001/jamapsychiatry.2025.3639.

2. Correll CU, Detraux J, De Hert M. Cardiovascular disease and mortality in people with mental illness. Lancet Psychiatry. 2017;4(12):957-970.

3. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analysis of randomised controlled trials. BMJ. 2012;344:d7771.